Dr. Pawel Kalinski is currently a Professor in the Departments of Surgery, Immunology, Infectious Diseases and Microbiology, and Bioengineering at the University of Pittsburgh. Dr. Kalinski is the Director of Research and the Director of the Immunotransplantation Center in the Division of Surgical Oncology of the University of Pittsburgh Cancer Institute.
Dr. Kalinski received his MD from the Warsaw University Medical School in Warsaw, Poland, and then went on to the University of Amsterdam, Amsterdam, The Netherlands, to receive his PhD in Immunology in 1998. Following his graduation, Dr. Kalinski did postgraduate work in the Department of Cell Biology and Histology at the Academic Medical Center, a division of the University of Amsterdam.
The goal of Dr. Kalinski’s research is to advance the inclusion of immunotherapy into comprehensive care of cancer patients. His group aims to develop methods of using ex vivo-educated dendritic cells (type-1-polarized DCs) induced in the conditions that mimic acute viral infections or combinatorial adjuvants to selectively induce type-1 effector- and memory-type CTLs and Th1 cells, without amplifying the pre-existing Treg responses or MDSC activity in cancer patients. The lab’s second goal is to promote selective homing of anti-cancer effector cells to tumor lesions and to enhance their local anti-tumor functions, with concomitant suppression of intratumoral accumulation of regulatory cells. Finally, Dr. Kalinski and his team aim to develop ways of priming lymph nodes for enhanced attraction of DCs, naïve and memory T cells, with simultaneous exclusion of Tregs, in order to amplify the induction phase of anti-cancer immunity. The lab’s current work includes phase I/II and phase II clinical testing of the resulting paradigms and methods as treatments for cancer patients, and the development of similar treatments for patients with premalignant lesions and chronic infections resistant to standard forms of treatment.
Dr. Kalinski is a member of the American Association of Immunologists (since 2001), the Society for Natural Immunity (since 2004), the Society for Immunotherapy of Cancer (since 2008, and since 2011 a Member of the Board of Directors), the Society for Clinical and Translational Science (since 2009), and the American Association for Cancer Research (since 2011). Most recently, Dr. Kalinski was the recipient of the 2010 International Society for Biological Therapy of Cancer (iSBTc)/Society for Immunotherapy of Cancer (SITC) Team Science Award. Dr. Kalinski is the Founding Member of the Editorial Board of OncoImmunology and the Associate Editor of the Journal for Immunotherapy of Cancer. He also serves as a reviewer for many journals, namely Nature Nanotechnology, Lancet Oncology, Science Translational Medicine, Cancer Research, and others.
View a list of Dr. Kalinski’s publications here.